New Drug Combination Shows High Remission Rates in Acute Myeloid Leukemia

Synergistic and antagonistic drug interactions are prevalent but not conserved across acute myeloid leukemia cell lines

Acute myeloid leukemia (AML) is the most prevalent type of leukemia in adults. Its heterogeneity, both between patients and within the same patient, is often a factor contributing to poor treatment outcomes. Despite advancements in AML biology and medicine in general, the standard AML treatment, the combination of cytarabine and daunorubicin, has remained the same for decades. Combination drug therapies are proven effective in achieving targeted…

New drug combination shows high remission rates in acute myeloid leukemia

A combination therapy that adds a recently approved drug to the current standard of care for newly diagnosed acute myeloid leukemia (AML) showed high rates of complete remission in an early-phase clinical trial conducted at UNC Lineberger Comprehensive Cancer Center and 11 other sites nationwide.

Combination therapy found safe and beneficial for acute myeloid leukemia patients with specific genetic profile

A combination therapy that adds a recently approved drug to the current standard of care for newly diagnosed acute myeloid leukemia (AML) showed high rates of complete remission in an early-phase clinical trial conducted at UNC Lineberger Comprehensive Cancer Center and 11 other sites nationwide.

Dasatinib Misses Survival End Points in Core-Binding Factor AML

Compared with standard therapy, dasatinib did not improve efficacy for patients with core-binding factor AML.

Precision Drug Combination Achieves 88% Response in Older Leukemia Patients

A drug combination regimen has shown high response and remission rates in patients 60 years and older who are newly diagnosed with acute myeloid leukemia (AML). The treatment introduces a recently approved cancer drug, revumenib, to the standard of care for patients carrying one of two genetic abnormalities linked with the development and progression of this form of cancer.  “This regimen has the potential to be practice-changing for patients wh…

Prognosis and Perception of KMT2A AML

Panelists emphasize that patients with KMT2A-rearranged acute myeloid leukemia (AML) often face steep educational challenges at diagnosis, requiring clear communication about the subtype’s adverse-risk classification, biological complexity, and treatment implications—highlighting the need for accessible education, academic-community collaboration, and early referral to specialized care for optimal outcomes.